首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷癌症個人化醫學分子呈像/呈影劑核子醫學

放射性藥物治療診斷學市場規模、佔有率及成長分析（按類型、來源、應用、最終用戶和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1919879

放射性藥物治療診斷學市場規模、佔有率及成長分析（按類型、來源、應用、最終用戶和地區分類）－2026-2033年產業預測

Radiopharmaceutical Theranostics Market Size, Share, and Growth Analysis, By Type, By Source, By Application, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月06日 | 出版商:

SkyQuest | 英文 187 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球放射性藥物治療診斷學市場規模將達到 23 億美元，到 2025 年將達到 25.7 億美元，到 2033 年將達到 62.3 億美元，在預測期（2026-2033 年）內，複合年成長率為 11.7%。

隨著癌症和神經系統疾病發病率的不斷上升，標靶治療的需求日益迫切，全球放射性藥物治療診斷學市場正蓬勃發展。這種創新方法整合了診斷和治療功能，透過提高效率和改善治療效果來提升患者照護。精準醫療的日益普及、核醫領域投資的不斷成長以及影像技術的進步，正推動著該技術在醫院和研究機構的廣泛應用。在監管機構的支持以及與製藥和生物技術公司的合作推動下，該領域的未來前景十分光明，這些合作旨在促進創新並拓展全球市場。然而，高昂的研發成本、嚴格的法規結構、有限的同位素供應、安全隱患以及基礎設施不足等挑戰，可能會阻礙該技術在某些地區的廣泛應用。

全球放射性藥物治療診斷學市場促進因素

全球放射性藥物治療診斷學市場的發展動力源自於放射性藥物獨特的標靶治療能力，即能夠同時診斷和治療疾病。這種雙重功能使臨床醫生能夠最大限度地減少對健康組織的輻射暴露，從而改善患者預後並縮短復原時間。治療診斷學療法在現代醫學中日益重要，能夠有效應對複雜的疾病狀態，尤其是在癌症和某些神經退化性疾病領域。標靶治療的整合不僅簡化了治療流程，還提供了更個人化的患者照護方案，顯著促進了市場成長。

全球放射性藥物治療診斷學市場面臨的限制因素

全球放射性藥物治療診斷學市場面臨的主要限制因素是醫用同位素供應有限，尤其是在缺乏本地生產設施的地區。這種短缺，加上運輸和儲存方面的挑戰，阻礙了患者及時獲得治療。此外，嚴格的法規結構增加了對集中供應商的依賴，使分銷流程更加複雜。因此，醫療機構可能難以確保治療診斷學解決方案的穩定及時供應，最終影響患者的治療效果和市場的整體成長潛力。應對這些挑戰對於提高治療診斷學應用的可近性和效率至關重要。

全球放射性藥物治療診斷學市場趨勢

全球放射性藥物治療診斷學市場正經歷著一場變革性趨勢：個人化治療診斷學方法的興起。這項創新反映了精準醫療的廣泛發展趨勢，它能夠開發出針對個別患者特徵設計的放射性藥物，從而實現診斷和治療的同步進行。透過提高標靶治療的療效並最大限度地減少副作用，這種個人化模式顯著改善了患者的治療效果，並提升了患者的整體體驗，尤其是在腫瘤學和神經病學領域。隨著醫療保健產業不斷重視個人化醫療，對這些先進治療診斷學解決方案的需求預計將大幅成長，從而推動市場成長並支持持續的研發投入。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Novartis AG
Bayer AG
Eli Lilly and Company
Bristol Myers Squibb
AstraZeneca
Telix Pharmaceuticals
Lantheus Holdings, Inc.
ITM Isotope Technologies Munich SE
GE HealthCare
Siemens Healthineers
Curium Pharma
Radiopharm Theranostics
Jubilant Pharmova
Eckert & Ziegler
Clarity Pharmaceuticals
Actinium Pharmaceuticals
Ariceum Therapeutics
RadioMedix, Inc.
NorthStar Medical Radioisotopes
Aktis Oncology

結論與建議

簡介目錄

Product Code: SQMIG35I2494

Global Radiopharmaceutical Theranostics Market size was valued at USD 2.3 billion in 2024 and is poised to grow from USD 2.57 billion in 2025 to USD 6.23 billion by 2033, growing at a CAGR of 11.7% during the forecast period (2026-2033).

The global radiopharmaceutical theranostics market is experiencing significant momentum driven by the increasing prevalence of cancers and neurological conditions, highlighting the need for targeted therapies. This innovative approach integrates diagnostic and therapeutic capabilities, enhancing patient care through improved efficiency and outcomes. Growing emphasis on precision medicine, coupled with heightened investments in nuclear medicine and advancements in imaging technologies, is fostering broader acceptance and implementation in hospitals and research institutions. This sector's future appears promising, buoyed by regulatory support and collaborations with pharmaceutical and biotechnology firms that aim to drive innovation and facilitate global market entry. However, challenges such as substantial development costs, stringent regulatory frameworks, limited isotope availability, safety concerns, and a lack of infrastructure may impede widespread adoption in certain regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Radiopharmaceutical Theranostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Radiopharmaceutical Theranostics Market Segments Analysis

Global Radiopharmaceutical Theranostics Market is segmented by Type, Source, Application, End User and region. Based on Type, the market is segmented into Companion Diagnostic Radiopharmaceuticals and Targeted Therapeutic Radiopharmaceuticals. Based on Source, the market is segmented into Nuclear Reactors and Cyclotrons. Based on Application, the market is segmented into Oncology, Cardiology, Neurology and Other Applications. Based on End User, the market is segmented into Hospitals, Diagnostic Imaging Centers, Research Institutes and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Radiopharmaceutical Theranostics Market

The global radiopharmaceutical theranostics market is driven by the unique capability of radiopharmaceuticals to simultaneously diagnose and treat diseases through one targeted approach. This dual functionality allows clinicians to minimize exposure to healthy tissues, leading to enhanced patient outcomes and shorter recovery periods. By effectively addressing intricate disease conditions, particularly in the realm of cancer and specific neurodegenerative disorders, theranostic therapies are becoming increasingly vital in modern medicine. The integration of targeted therapies not only streamlines the treatment process but also provides a more personalized approach to patient care, thereby significantly contributing to the market's growth.

Restraints in the Global Radiopharmaceutical Theranostics Market

A significant limitation in the Global Radiopharmaceutical Theranostics market is the restricted availability of medical isotopes, especially in regions lacking local production facilities. This scarcity, coupled with challenges related to transportation and storage, hinders timely access to treatments for patients. Furthermore, stringent regulatory frameworks intensify the dependence on centralized suppliers, thereby complicating the distribution process. As a result, healthcare providers may struggle to ensure consistent and timely delivery of theranostic solutions, which could ultimately affect patient outcomes and the overall growth potential of the market. Addressing these issues is crucial for enhancing accessibility and efficiency in theranostic applications.

Market Trends of the Global Radiopharmaceutical Theranostics Market

The Global Radiopharmaceutical Theranostics market is witnessing a transformative trend characterized by the rise of tailored theranostic approaches. This innovation reflects the broader movement towards personalized medicine, enabling the development of radiopharmaceutical agents designed to cater to individual patient profiles for simultaneous diagnosis and treatment. By enhancing targeted therapeutic efficacy while minimizing adverse effects, this personalized model significantly improves patient outcomes and elevates the overall patient experience, particularly in oncology and neurology. As healthcare continues to prioritize individualized care, the demand for these advanced theranostic solutions is expected to surge, driving market growth and fostering ongoing research and development.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Radiopharmaceutical Theranostics Market Size by Type & CAGR (2026-2033)

Market Overview
Companion Diagnostic Radiopharmaceuticals
Targeted Therapeutic Radiopharmaceuticals

Global Radiopharmaceutical Theranostics Market Size by Source & CAGR (2026-2033)

Market Overview
Nuclear Reactors
Cyclotrons

Global Radiopharmaceutical Theranostics Market Size by Application & CAGR (2026-2033)

Market Overview
Oncology
Cardiology
Neurology
Other Applications

Global Radiopharmaceutical Theranostics Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Diagnostic Imaging Centers
Research Institutes
Other End Users

Global Radiopharmaceutical Theranostics Market Size & CAGR (2026-2033)

North America (Type, Source, Application, End User)
- US
- Canada
Europe (Type, Source, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Source, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Source, Application, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Source, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Telix Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus Holdings, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ITM Isotope Technologies Munich SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE HealthCare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curium Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Radiopharm Theranostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Pharmova
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eckert & Ziegler
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clarity Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Actinium Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ariceum Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RadioMedix, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NorthStar Medical Radioisotopes
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aktis Oncology
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments